Z-VAD-FMK

Catalog No.S7023

Z-VAD-FMK Chemical Structure

Molecular Weight(MW): 467.49

Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.

Size Price Stock Quantity  
USD 117 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 501 Publications

Purity & Quality Control

Choose Selective Caspase Inhibitors

Biological Activity

Description Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.
Features A key compound for apoptosis studies.
Targets
Pan-caspase [1]
(THP.1, Jurkat T-cells)
In vitro

Z-VAD-FMK (10 mM) inhibits apoptosis in THP.1 cells. Z-VAD-FMK (10 μM) inhibits activation of PARP protease activity in control THP.1 cell lysates. Z-VAD-FMK (10 mM) inhibits the processing of CPP32 in intact THP.1 and Jurkat cells. [1] Z-VAD-FMK (50 μM) cotreatment abolishes the apoptotic morphology of camptothecin-treated HL60 cells. Z-VAD-FMK (50 μM) blocks camptothecin-induced DNA fragmentation in HL60 cells. [2] Z-VAD-FMK (50 μM) inhibits cell death following dSMN dsRNA-induced apoptosis in S2 cells. Z-VAD-FMK (50 μM) increases the percentage of transfected cells surviving from 26% to 63% in S2 cells. [3] Z-VAD-FMK (> 100 μM) enhances TNFα-induced neutrophil apoptosis, lower concentrations (1-30 μM) completely blocks TNFα-stimulated apoptosis in human neutrophils. [4] Z-VAD-FMK (10 mM) inhibits apoptosis in anterior stromal keratocytes. Z-VAD-FMK (10 mM) inhibits apoptosis in anterior stromal keratocytes detected with the TUNEL assay. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
GC1a NH\COXRCeG:ydH;zbZMhSXO|YYm= MX:1NO69VQ>? Mo\oNlRp MV7pcoRq[2G2ZYOgZUBxem:2ZXP0bZZmKGWoZnXjeEBi\2GrboP0JIV1d3Cxc3nk[S=> MXqyOlE3QTB5NR?=
HGL5 MY\BdI9xfG:|aYOgRZN{[Xl? MnPqOVDPxE1? MnvsNlRp MmOxbY5lcWOjdHXzJIEheHKxdHXjeIl3\SCnZn\lZ5Qh[WejaX7zeEBmfG:yb4Pp[IU> NV24RnNrOjZzNkmwO|U>
HepG2 M{m0ZmFxd3C2b4Ppd{BCe3OjeR?= M3zIblIx|ryP MofDNYg> M3\UfIF1fGWwdXH0[YQhfGinIHHwc5B1d3SrYzDpcoR2[3Srb36gc4YhUUmLLUGwxsA> NFzTVWozPjF4NEe5OS=>
BEL-7402 M3j4e2Fxd3C2b4Ppd{BCe3OjeR?= NIrORpEzOM7:TR?= MkfRNYg> M3XUbYF1fGWwdXH0[YQhfGinIHHwc5B1d3SrYzDpcoR2[3Srb36gc4YhUUmLLUGwxsA> NIf4fHAzPjF4NEe5OS=>
CEF MXnLbY5ie2ViQYPzZZk> NInoOWoxNDN|LE[3MFExOM7:TR?= Mn71NVVucW5? NYD4dHNM\G:5bj3y[Yd2dGG2ZYOgVHIh\W68eX3lJIFkfGm4aYT5JJRwKDRy78{FJIF1KDFyMN88US=> MofrNlYyODJ|M{m=
SP2/0 M4TBOmFxd3C2b4Ppd{BCe3OjeR?= MWmxNFDPxE1? NXL6S45MOWh? MmrySG1UVw>? MorUZoxw[2u|IITo[UBieG:ydH;zbZMhd2ZiU2CyM|Ah[2WubIO= NHj6WVMzPjB5NEezNi=>
HUVEC-2c MUjBdI9xfG:|aYOgRZN{[Xl? M1TrT|Ux|ryP M4PRR|Zp NYrLTZBF\GWlcnXhd4VlKHSqZTDvfE1NTExvaX7keYNm\CCjdYTvdIhi\3l? NUXkdHRDOjZyMkG3Nlk>
U1 MXnBdI9xfG:|aYOgRZN{[Xl? NXrYb|hEOC1zMEFOwG0> NHqxXWwzcA>? MWDy[YR2[2W|IHTyeYcucW6mdXPl[EBieG:ydH;zbZMh[W6mIIP1ZpNmeXWnboSgTGlXNTFicnXwcIlk[XSrb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M2rCRlI2QThyOUSy
ACH-2 NHvu[ZpCeG:ydH;zbZMhSXO|YYm= M3r2bVAuOjByzszN MmnNNog> NEPPV|Rz\WS3Y3XzJIRzfWdvaX7keYNm\CCjcH;weI9{cXNiYX7kJJN2[nOncYXlcpQhUEmYLUGgdoVxdGmlYYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NUDEclNZOjV7OEC5OFI>
U1 NXPhWWdUU2mwYYPlJGF{e2G7 Mk\INVAx|ryP NHTk[W4zcA>? NHnyW|JqdmirYnn0d{Bk[XOyYYPlMVM> NXjjSmlTOjV7OEC5OFI>
A549/V16 M1;nRWFxd3C2b4Ppd{BCe3OjeR?= MXy1NO69VQ>? MkDmNYg> MoKydoVxemW|c3XzJHRIN1SPLXnu[JVk\WRiYYDvdJRwe2m| Mnf5NlU6PDZyM{O=
SGN MYTBdI9xfG:|aYOgRZN{[Xl? MW[yNI1O NFqySY81QGh? MnTXbIF{KG6xIHnu[ox2\W6lZTDvckBCUUZuIHPhcJBicW5iZYjwdoV{e2mxbjDvdkBk\WyuIHHwc5B1d3Orcx?= MlnmNlU5PzR4M{O=
HCT116  NWDqbnptSXCxcITvd4l{KEG|c3H5 NUDWdoJoPTEQvF2= MXmybC=> M{jOe4lvcGmkaYTzJJRp\SClZXzsJIRm[XSqIHnu[JVk\WRiYomgSGRXWA>? NW\sWWlFOjV6Nki4NVg>
DTK-SME NXm0PJIySXCxcITvd4l{KEG|c3H5 NID3U2U2OM7:TR?= Mlr2Nog> M{\hPWROW09? NGqzOJBx[XK2aXHscJkhcW6qaXLpeJMhfGinIHHwc5B1d3OrczDpcoR2[2WmIHL5JIJ2eGm4YXPhbY5m NIjvNFUzPTh2M{i5Oy=>
HL-60 M4q1UmFxd3C2b4Ppd{BCe3OjeR?= MoLqOVDPxE1? Mn7oOFhp NFPX[Yxz\WS3Y3XzJINmdGxiZHXheIgh[2G3c3XkJIJ6KFONST3JTUB1emWjdH3lcpTDqA>? NF\FToszPTh{NEC0Ny=>
U937 MXLBdI9xfG:|aYOgRZN{[Xl? M2r4eVUx|ryP Mkm0OFhp M1LyeJJm\HWlZYOgZ4VtdCCmZXH0bEBk[XW|ZXSgZpkhW0uLLVnJJJRz\WG2bXXueOKh NVjYd5JLOjV6MkSwOFM>
A549 M{XzemFxd3C2b4Ppd{BCe3OjeR?= MlLENlAh|ryP NYX3RWZWOjSq NEXqTIpz\WS3Y3XzJINmdGxiZHXheIgh[2G3c3XkJIJ6KEiIQ2CgeJJm[XSvZX70 MVKyOVc6PDF2OR?=
HeLa MXzBdI9xfG:|aYOgRZN{[Xl? NFv6e3MyOM7:TR?= Mm[2OFhp NX2zV4Rj\GWlbHnu[ZMhfGinIILheIUhd2ZiYYDvdJRwe2m|IHTyZY1ifGmlYXzsfS=> M1zqNFI2Pzd{NUS1
SGC-7901 M3nDeGFxd3C2b4Ppd{BCe3OjeR?= NHXVS2IzOMLizszN M2fOOFFp Mk\2bY5pcWKrdIOgeIhmKGOnbHyg[IVifGhiaX7keYNm\CCkeTDvfIFtcXCuYYTpci=> NEfzUngzPTd4N{C3Oi=>
MCF-7 NFvRXYNCeG:ydH;zbZMhSXO|YYm= MUWxNO69VQ>? NU\oemVPOmh? NGP5XXZqdmirYnn0d{B1cGViY3XscEBl\WG2aDDpcoR2[2WmIHL5JFND MWCyOVczOjFzNB?=
A549 NYXkOWdtSXCxcITvd4l{KEG|c3H5 NGPi[4MyOCEQvF2= MonKNlRp NUTkcHZ5TE2VTx?= M3fsRpBzd22xdHXzJGhDSy22cnXheIVlKEF3NEmgZ4VtdCC|dYL2bZZidCBoIHH0eIVvfWG2ZYOgeIhmKGOuZXH2[YQhWEGUUDDlfJBz\XO|aX;u MUWyOVY5OzV4OB?=
U87 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUK1NO69VQ>? NX\sXJhyOWh? MXzy[YNwfmW{czDj[YxtKGe{b4f0bEBnem:vIGTNXkB1emWjdH3lcpQ> Mlu1NlU3QDF4Nki=
Neocortical Neuron M1niU25mfXKxdH;4bYNqfHliQYPzZZk> NVnvWW8yOTByzszN M3qwTlFp NF[0b21idnSjZ3;ubZpmeyCKb3nhcYll\SCDLVnu[JVk\WRiTnX1do91d3irY3n0fS=> M4roU|I2Pjd3MECx
Primary human placental cytotrophoblasts MUfBdI9xfG:|aYOgRZN{[Xl? MmXZN|DPxE1? MUGyOIg> MnXSSG1UVw>? NVf0OoRyemW4ZYLz[ZMhfGinIHnubIljcXSrb36gc4YhOTIQsj3IV2QzKGK7IITybYNtd3OjbtMg MWKyOVY1OjV7Mh?=
MM MnzSRZBweHSxc3nzJGF{e2G7 NHPiboY2OM7:TR?= MYWyNI1qdg>? Ml;hdIFzfGy7IHnubIljcXS|IGPIT{1qdmS3Y3XkJEBk\WyuIHTlZZRp NXnJbWlEOjV3M{CwPVg>
DLD1 NVPmNpdCSXCxcITvd4l{KEG|c3H5 MUSyNOKh|ryP NHzybWsycA>? M2DmRpBienSueTDy[ZZmenOnczDj[YxtKGGyb4D0c5NqeyClYYXz[YQh[nliV2PQNS=> MmjxNlU2OjR{NE[=
MDA-MB-231 NULDNHNiS3m2b4TvfIlkcXS7IFHzd4F6 NInUNmoyOM7:TR?= M3TLbFFp M3fWXYF2\22nboTzJINmdGxiZHXheIgh[W[2ZYKgR2hWSSC2cnXheI1mdnR? NInHZXEzPTV{MUWwNS=>
MKN28 M2HDeWFxd3C2b4Ppd{BCe3OjeR?= M2PucFEx|ryP M1LHblMxdWmw MlfxSG1UVw>? MYfpcohq[mm2czDUUmYu|rFicHz1d{BEUFhvaX7keYNm\CCjcH;weI9{cXN? Mlz1NlU2OTN7NkC=
HL-60 NF\IcGZEgXSxdH;4bYNqfHliQYPzZZk> MnLlNVAx|ryP NITrcHYycA>? NVridFBRTE2VTx?= M3TLS:KhcW2ycn;2[ZMhfmmjYnnsbZR6KG:oIGTDUmF{NXS{ZXH0[YQh[2WubIO= MVWyOVUxOjl|Mh?=
AGS M3L4SWFxd3C2b4Ppd{BCe3OjeR?= M37pRlEx|ryP MX2xbC=> NFO0N3NxemW4ZX70d{BkfXKldX3pck1qdmS3Y3XkJINt\WG4YXflJI9nKGOjc4Dhd4UuOyxiLUisJIFv\CBvOTDwdo91\Wmwcx?= NITud48zPTR7MkKxOC=>
A549  MULBdI9xfG:|aYOgRZN{[Xl? NED3[pQyOM7:TR?= NITXXnEzPGh? M4jlSYJtd2OtczDEUWFUNWmwZIXj[YQh[2ynYY\h[4Uhd2ZiY3HzdIF{\S1|IHHu[EBRSVKSIHHu[EBieG:ydH;0bYMh[2WubDDk[YF1cA>? NF3ibGwzPTR|NEm4PS=>
INS-1 M{fObGFxd3C2b4Ppd{BCe3OjeR?= NFW1SXk2OM7:TR?= M3jMcVZp MXrEUXNQ NE[0RnVl\WO{ZXHz[ZMhfGinIIDyc5BwenSrb36gc4Yh\WG{bImgZZBweHSxdHnjJINmdGy|wrC= NVrjUHNrOjV2M{C4PVc>
Primary hepatocytes  MUfBdI9xfG:|aYOgRZN{[Xl? M3TEPVUx|ryP NELBOnUyQGh? NXznR5htcW6qaXLpeJMh[XCxcITvd4l{KG:oIHjldIF1d2O7dHXzJIlv\HWlZXSgZpkhSWO2IFSgZY5lKFSQRj5OtS=> NWTHU4NVOjV2MEe1N|g>
L929-A  MmW1R5l1d3SxeHnjbZR6KEG|c3H5 MWCyNOKh|ryP MVGyOIg> MVLpcohq[mm2czDUUmbPuS2rbnT1Z4VlKGOnbHyg[IVifGh? M1fJ[|I2Ozl6NUSw
L929-N MUXDfZRwfG:6aXPpeJkhSXO|YYm= NFvJcXgzOMLizszN NYPVWJFiOjSq NWXxPVlS\W6qYX7j[ZMh\GWjdHigeoliKGG3dH;jdolv\SCWTldOtUBxem:mdXP0bY9v MV2yOVM6QDV2MB?=
Cytotoxicity Assay MXrD[YxtKF[rYXLpcIl1gSCDc4PhfS=> Ml;xNlDPxE1? MlPpOFhp NUfFe|lteHKndnXueEBOUE2GLXnu[JVk\WRiY3XscEBl\WG2aB?= M{TBO|I2Ozl{MUG2
COS7 M{D3WGtqdmG|ZTDBd5NigQ>? NUTmXGxZOTEQvF2= NWHZR3FNOjSq NVjpS5hucW6lcnXhd4V{KGOjc4Dhd4UhOy95IHHjeIl3cXSrZYO= M1H4WVI2Ozh2MEK1
COS7 MlG1RZBweHSxc3nzJGF{e2G7 MYCxNO69VQ>? Mn7VOFhp NFnsNZNx[XK2aXHscJkheHKndnXueIVlKE[FMUCxMYlv\HWlZXSgZ4VtdCCmZXH0bC=> NUPnUo9vOjV|OESwNlU>
A375 M3;CZmFxd3C2b4Ppd{BCe3OjeR?= M4jCT|Mx|ryP NIX5XoYzcA>? NWWwXGJZeHKndnXueJMhfGinIHTyeYcucW6mdXPl[EBRSVKSIHPs[YF3[Wen MoPHNlU{PzZzMUW=
A549 MmfHRZBweHSxc3nzJGF{e2G7 M4niSVUx|ryP MnPtNlRp M3zJRZJmfmW{c3XzJJJq[m:|b33lJIJqd2enbnXzbZMh[W6mIHHwc5B1d3OrczDjZZV{\WRiYomgJGNpcWqxbnfkZY4> M2fGflI2OzR7N{ix
A549 MVrBdI9xfG:|aYOgRZN{[Xl? NIKwVnIzNjVvMkZOwG0> M{fF[lFp MUXk[YNz\WG|ZYOgeIhmKHCxcIXsZZRqd25ib3[gZZBweHSxdHnjJINmdGy|IHTldIVv\CCxbjDjc45k\W62cnH0bY9vew>? Mly2NlU{PDJ2Mke=
 NBL-W-S  M17JT2Fxd3C2b4Ppd{BCe3OjeR?= M3;LWlUx|ryP MXSxbC=> MXPmeYxtgSC{ZYPjeYV{KGOnbHygeoli[mmuaYT5JIFnfGW{IFfBUnQuPjFidILlZZRu\W62 MkLGNlU{OjN{MkK=
Caki-1  Ml3uRZBweHSxc3nzJGF{e2G7 MVG0NO69VQ>? Mo\COFhp MVLy[YR2[2W|IITo[UBvfW2kZYKgc4YhSW6wZYjpckBXNXCxc3n0bZZmKGOnbHzz NXLueZc2OjV{N{mxPVE>
769-P NFL6eIVCeG:ydH;zbZMhSXO|YYm= NX\USVhyPDEQvF2= NHTucYk1QGh? M1G2WpJm\HWlZYOgeIhmKG63bXLldkBw\iCDbn7lfIlvKFZvcH;zbZRqfmViY3XscJM> NIjaSpczPTJ5OUG5NS=>
H9c2 Mki1RZBweHSxc3nzJGF{e2G7 MmjsOVDPxE1? Mlz6NYg> M{XNeYlvcGmkaYTzJGRQYC2rbnT1Z4VlKGOjc4Dhd4UhOyCjY4TpeoF1cW:wIHL1eEBvd3RidHjlJIxwe3Nib3[gZ4VtdHN? M2TENVI2Ojh|OEG5
K562 NWPLRlZxSXCxcITvd4l{KEG|c3H5 MlzDOVDPxE1? NFP5fYE1cA>? NWnRcmRGcW6qaXLpeJMhUmGlLVGtbY5lfWOnZDDj[YxtKGGyb4D0c5Nqew>? NEfQVFMzPTJ2MU[xPS=>
L929 MVnBdI9xfG:|aYOgRZN{[Xl? MknRNVDPxE1? M3q4RlZp NVjxSFRJcW6mdXPld{Bv\WO{b4D0c5NqeyC5aYToJHRPTg>? NY\CVVJCOjVzOUW2OlA>
A549 MlL2RZBweHSxc3nzJGF{e2G7 MoXmNVDPxE1? NHHvfW4{cA>? MoKzdoVlfWOnczDj[YxtKGGyb4D0c5NqeyClYYXz[YQh[nliUGHR NV;BWY02OjVzNkG2PVk>
MCF-7 Mn63RZBweHSxc3nzJGF{e2G7 M1PKUVIx|ryP NIHab5kzcA>? NFmwXHJl\WO{ZXHz[ZMhU0SULYPpVm5CNWmwZIXj[YQh[XCxcITvd4l{ NEfHUlgzPTF6MkK0NC=>
OS NHvQV|RCeG:ydH;zbZMhSXO|YYm= M4HMZ|IxNzRyzszN NGPMfpA4Omh? NVfWO|JlcW6qaXLpeJMhV1NiY3XscEB3cWGkaXzpeJkhemWmdXP0bY9vKGK7IFO2JINmemGvaXTl MU[yOVE2OjN7OR?=
HUVECs NVfEZ4N{SXCxcITvd4l{KEG|c3H5 NUThNoV6OTEQvF2= NHT6V4czcA>? MXhCpIlvcGmkaYTzJIFxd3C2b4Ppd{BidmRiZnHjbYxqfGG2ZYOgZZV1d3CqYXf5JIlvKESHTm[yMYlv\mWldHXkJGhWXkWFcx?= MkezNlUyOzh5MEO=
EA.hy926 NWLxNVJJSXCxcITvd4l{KEG|c3H5 MoKzNVDPxE1? MXGybC=> NGTyS2rDqGmwaHnibZR{KGGyb4D0c5NqeyCjbnSg[oFkcWyrdHH0[ZMh[XW2b4DoZYd6KGmwIFTFUnYzNWmwZnXjeIVlKEWDLnj5PVI3 NXPnW4JMOjVzM{i3NFM>
Ebs M{TQWGFxd3C2b4Ppd{BCe3OjeR?= NXnqVZJoOTBvMUCw{txO M4LlZVI1cA>? MojCxsBOVVSVIHflcoVz[XSrb36gdoF1\SCmZXPy[YF{\WRiYYOgeIhmKGOxbnPlcpRz[XSrb36gc4Yhgi2YQVSu[o1sKGmwY4LlZZNm\A>? Mo\ONlUyOzR6MUe=
Jurkat MX3BdI9xfG:|aYOgRZN{[Xl? NUK5fGlMOjEQvF2= M{nlWlI1cA>? NF\qV5VFVVOR MUTwZZJ1cWGubImgbY5pcWKrdDDj[YxtKGSnYYToJI9nKEq3cnvheEBk\WyuczDpcoR2[2WmIHL5JFExODV6LV[0JINwdWKrbnXkJJdqfGhiVmDBxsA> NETZbmozPTF{MEeyNy=>
K562 MVzBdI9xfG:|aYOgRZN{[Xl? NHrNNXoxNjFvMd88US=> M1S1[FFp MVrpcohq[mm2czDjcIVifmGpZTDv[kBJW1B7MDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NEDyPWQzPTFzOUG4PC=>
IMR-32 MYXBdI9xfG:|aYOgRZN{[Xl? M{f4RlQxyqEQvF5CpC=> MnHCNog> NUXCUXJy\GWlcnXhd4UhcW5iYYDvdJRwfGmlIHPlcIx{KGOxbYDhdoVlKHSxIGStNkB1d3irbh?= MkPQNlUxQDR5NUW=
RPMI 8226 MVvBdI9xfG:|aYOgRZN{[Xl? MXexNFDPxE1? NVLE[HQ{OWh? M1fCeIFtdW:|dDDjc41xdGW2ZXz5JIJtd2OtczDj[YxtKGSnYYToJINifXOnZDDifUBv\WO{b4P0ZZRqdi1z NHXPfmMzPTB|N{i1NS=>
U266  M3e4UmFxd3C2b4Ppd{BCe3OjeR?= M4LPZlExOM7:TR?= MmWxNYg> NF3FSpVx[XK2aXHscJkh[myxY3vzJINmdGxiZHXheIgh[2G3c3XkJIJ6KG6nY4Lvd5RifGmwLUG= MUiyOVA{Pzh3MR?=
H929  M{HCWmFxd3C2b4Ppd{BCe3OjeR?= Ml7TNVAx|ryP MXqxbC=> NYmzOnFNeGG{dHnhcIx6KGKub3Prd{Bk\WyuIHTlZZRpKGOjdYPl[EBjgSCwZXPyc5N1[XSrbj2x MV[yOVA{Pzh3MR?=
MM.1S  MXLBdI9xfG:|aYOgRZN{[Xl? MXixNFDPxE1? M2HLeVFp MX3l[oZq[2mnboTsfUBxemW4ZX70d{B{d3KjZnXubYIucW6mdXPl[EBk\WyuIHTlZZRpKGOxbXLpcoUhf2m2aDDu[YNzd3O2YYTpck0y NFrUcngzPTB|N{i1NS=>
C6 MXrBdI9xfG:|aYOgRZN{[Xl? MX21NO69VQ>? NVruVWJZPDiq M3XGNZBz\X[nboTzJJRp\SCub4PzJI9nKGOnbHygeoli[mmuaYT5JINifXOnZDDifUBxemWpbnXuc4xwdmV? MlPFNlUxOTN2N{m=
AGS MoDIRZBweHSxc3nzJGF{e2G7 NX\RRplDPTEQvF2= NXTWfWhpOjSq MlL3ZYJwdGm|aIOg{tIudGGyYXPoc45mNWmwZIXj[YQh[2WubDDk[YF1cCCjbnSgbY5pcWKrdHXkJIdzd3e2aB?= NH;JSZEzPTByOU[5PC=>
HeLa  NUnzOG84SXCxcITvd4l{KEG|c3H5 M{K3VFQx|ryP NX3jVVJrOjSq NIHPfJpqdmirYnn0d{B1cGViaX7jdoVie2WmIHHwc5B1d3OrczDpcoR2[2WmIHL5JJNqWk6IMUKx NG\0dnMzPDl{OE[4OS=>
THP-1  NEDmSohCeG:ydH;zbZMhSXO|YYm= NIDK[WgyOM7:TR?= MVGxbC=> MoHydoVlfWOnczDhdI9xfG:|aYOgbY5lfWOnZDDifUBCVEFvU1TUxsA> NWPOe3ZsOjR7MkO2OVM>
P815  NIfRNmVCeG:ydH;zbZMhSXO|YYm= M3\xdFExOCEEtV2= NHLrWGwyOmh? MlqzSG1UVw>? Mmj3bY5pcWKrdIOgeolzfXNvaX7keYNm\CCjcH;weI9{cXN? NVHYVmRrOjR7MkOyO|M>
HCT116 M4\TbWFxd3C2b4Ppd{BCe3OjeR?= M1zx[lIx|ryP NGHPSmkzPGh? MmLWZYJzd2ejdHXzJI9nKFSTLXnu[JVk\WRiYYDvdJRwe2l? NHexfoQzPDh7MES0PS=>
SW1116  NEX1dppCeG:ydH;zbZMhSXO|YYm= NF;UXWcyOCEEtV2= NVjrR|FMOWh? M3\Sb2ROW09? NHLXW3lz\XO2cnHpcpMh[2WubDDhdI9xfG:|aYOgbY5lfWOnZDDifUBo\W[rdHnubYIheGy3czDk[YNqfGGkaX7l MXuyOFg4PDJ6Nh?=
LOVO NWrZNmVrSXCxcITvd4l{KEG|c3H5 M{nWflExKML3TR?= M2r1UVFp NEnEVXlFVVOR NHPWT4hz\XO2cnHpcpMh[2WubDDhdI9xfG:|aYOgbY5lfWOnZDDifUBo\W[rdHnubYIheGy3czDk[YNqfGGkaX7l NUfCXmN3OjR6N{SyPFY>
SNU449  NHLKNlBCeG:ydH;zbZMhSXO|YYm= NWfCcohZOjEQvF2= NX;HTZdGPDiq NI\6OGJFVVOR M4freYRm[3KnYYPld{BucVJvNEWxMYlv\HWlZXSgZZBweHSxdHnj MWCyOFg1OTZ|OB?=
Caco-2 M{PXUmFxd3C2b4Ppd{BCe3OjeR?= NVnjdZQzPDEkgJpOwG0> NELsN3Y1cA>? NH;wd2dxemW4ZX70d{BUXC15LXnu[JVk\WRiWl:tNUBkcGGwZ3XzJIFv\CCWRWKg[JJweA>? M2m3UFI1QDJ{MUiz
macrophage NVnpSllLS2WubDDWbYFjcWyrdImgRZN{[Xl? MVmwMVIxOM7:TR?= NHjHW|UzPGh? MoPubY5lfWOnczDUUmYuKGGwZDDSbZA{NWSncHXu[IVvfCCwZXPyc5B1d3OrczDpckBu[WO{b4DoZYdm M{O1VlI1Pzl7NU[1
AGS  M3vrVmFxd3C2b4Ppd{BCe3OjeR?= NFTZZ2MzOM7:TR?= MWexNog> NWTiUpQ5TE2VTx?= NFvJUWhz\WS3Y3XzJJRp\SCrbnT1Z5Rqd25ib3[gZZBweHSxc3nzJIlvKHKnc4DvcpNmKHSxIITo[UBGfE:DYzDmdoFkfGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M3G1UlI1Pzh7N{Cz
LCC9  NUHtUIdLS2WubDDWbYFjcWyrdImgRZN{[Xl? NHXkeGgyODEQvF2= M2DIZVVl M{O5dYJtd2OtczDj[YxtKGSnYYToJIlv\HWlZXSgZpkh[2:vYnnuZZRqd25iTEG3JIFv\CClaHzvdo9yfWmwZR?= NHP1V2kzPDd6NUK1Oi=>
U937  M3HHfo5m[3KxcITvd4l{KEG|c3H5 NHz1NW8yOMLizszN NGXsXHU{OMLibXnu Ml;jbY5lfWOnczDu[YNzd3C2b4Ppd{Bkd22kaX7lJJdqfGhiVF7G NV7qfXBuOjR5N{O3OVY>
T cell M3z1fmNmdGxicILvcIln\XKjdHnvckBie3OjeR?= M2rqcVAuOTByzszN NIjyOnQ4Omh? Mn7ETWM2OD15MDFOwG0tKGmwaHnibZR{KGGwdHmtR2Q{NWmwZIXj[YQhXCClZXzsJJBzd2yrZnXyZZRqd25iaX6gVGJOS3N? NGHlcFkzPDd4OEewOy=>
HeLa  Mm\DRZBweHSxc3nzJGF{e2G7 M2fqNVUx|ryP M4O2Z|czcA>? M1TUcWROW09? MUnwdoV3\W62czDhdI9xfG:|aYOgbY5lfWOnZDDifUBkd22yb4Xu[JPDqDIkgKO1 NGqxOZUzPDd3NEe4Oi=>
HeLa  NV;mfXJESXCxcITvd4l{KEG|c3H5 NYm5N5g5OTByzszN NVTacngyOjSq M1zlZpN2eHC{ZYPz[ZMhemG2ZTDv[kBk\WyuIHTlZZRpKGmwZIXj[YQh[nlib4\ldoV5eHKnc4Ppc44hd2ZiR{W5V{BweiCJN{HSJJAyPTCpbIXl[OKh MUeyOFczOjR4OB?=
IEC-6  Mmf1RZBweHSxc3nzJGF{e2G7 M3vYWFEx|ryP MWqyOIg> MVnwdoV3\W62czDUZ4RCNWmwZIXj[YQh[2G|cHHz[U0{KGOuZXH2ZYdmKGGwZDFOtk1k[XSnbnnuJIRm\3KjZHH0bY9v MofxNlQ4OTF3N{G=
HCT116 MlX1RZBweHSxc3nzJGF{e2G7 NY\mUYNPOjEQvF2= M4j2VFI1cA>? NYHXRVk3cW6qaXLpeJMhfGinIHPlcIwh[XCxcITveIlkKGmwZIXj[YQh[nliWVzUNlA2 NWHIS|Q3OjR5MUO4NVI>
L02 MmHCRZBweHSxc3nzJGF{e2G7 M1PlcFIx|ryP M{X6[FFp M4rGPJBz\X[nboTzJJRp\SClZXzsJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KE2HSGC= NUnoUFVCOjR5ME[0OlE>
A375 MlO2RZBweHSxc3nzJGF{e2G7 NIPtN28zOM7:TR?= NHPmUpQzPGh? MlPKdoV3\XK|ZYOg[IlkcXS{aX7vcoUhSi2rbnT1Z4VlKGGyb4D0c5Nqew>? MUiyOFY6QTFzMR?=
HDPC MYrBdI9xfG:|aYOgRZN{[Xl? NHnZfmc2OML3TR?= NWfYSmtNOjSq NGPBOldqdmirYnn0d{BPVy2rbnT1Z4VlKGGyb4D0c5Nqew>? M3fuU|I1PjN2NUmz
A549 NVrYO|VUSXCxcITvd4l{KEG|c3H5 Mk\SOVDDvU1? MVyybC=> M3i3[GROW09? MXzwdoV3\W62czD0bIUhcHmyb3TpdIxwcWRiRF7BJINwdnSnboSgdIhie2ViaX7keYNm\CCkeTDj[ZBp[WyxY3jyc41qdg>? MnHXNlQ2QDhzM{W=
 BV-2 NULRbHhVSXCxcITvd4l{KEG|c3H5 NGS5cVczOM7:TR?= M{DBflJp MlX0d5VxeHKnc4Pld{BWXi2rbnT1Z4VlKGOqcn;tZZRqdiCneITyeZNqd25iYX7kJIRqdGG2aX;uJI9nKHSqZTDueYNt\WG{IHXueoVtd3Cn NGXQfFczPDV3OEGxPC=>
HT-29  MmXCRZBweHSxc3nzJGF{e2G7 MXq1NO69VQ>? MWi0PIg> MUTicI9kc3NidHjlJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KGujZX3w[oVzd2x? NWi4emxEOjR3NEmxO|U>
A549 M4TFXGFxd3C2b4Ppd{BCe3OjeR?= NXf3VpNsPc7:TR?= NHrUN2gzPGh? NETM[3J{fXCycnXzd4V{KD[nwrCoRmsyODB2MDmtbY5lfWOnZDDhdI9xfG:|aYRCpC=> NHrYOJozPDV{OUi3NS=>
MIA-PaCa-2 M33Pd2Fxd3C2b4Ppd{BCe3OjeR?= MYOyOIg> MWTicI9kc3NiY3zlZZZi\2Vib3[gZ4F{eGG|ZT2zJIlv\HWlZXSgZpkh[m:2aDDBMVQ1OzZ3NDDhcoQheGGlbHn0ZZhmdA>? NWLLR4ZyOjR3MUC5PVI>
Caki-1 MUDBdI9xfG:|aYOgRZN{[Xl? MUGyNO69VQ>? MnfsNYg> NF\2T4xqdmirYnn0d{BUS1BvaX7keYNm\CCjcH;weI9{cXN? MUGyOFUxPDZ6MR?=
CLL MnWxRZBweHSxc3nzJGF{e2G7 MmKzNlXPxE1? MU[xbC=> Mle1dIFzfGmjbHz5JIJtd2OtczDNUG4zOjN6LXnu[JVk\WRiY3XscEBieG:ydH;zbZM> MVeyOFQ3PzZ|NB?=
SGC-7901 NUnRcnpVSXCxcITvd4l{KEG|c3H5 M2jQcVEx|ryP NFzjNYczPGh? MlnYdJJwdW:2ZYOgeIhmKEOJSVmtbY5pcWKrdHXkJINmdGxiZ4Lve5RpKGmwIGPHR{04QTBzIHPlcIx{ NXPyZ4N4OjR2NUS0PFg>
k1735 NUDCfmY{SXCxcITvd4l{KEG|c3H5 Moq5NlDjiIoQvH2= Mne4OIg> NFLGO2dqdmirYnn0d:KhW2GubX;u[Yxt[S2rbnT1Z4VlKGGyb4D0c5Nqew>? MYiyOFQ2OTFzNh?=
HaCaT  NIn1VYxCeG:ydH;zbZMhSXO|YYm= M{f3PVExOM7:TR?= NGrZRnUycA>? MV7icJVvfHNiVW\CMYlv\HWlZXSgZZBweHSxc3nzJIlvKEijQ3HUJINmdGy| NYHQbWplOjR|NU[5PVc>
podocytes MYHBdI9xfG:|aYOgRZN{[Xl? MoS1NlAx|ryP NXfidmFxPmh? MkTLbY5pcWKrdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkhOyx2LVTHSS=> M1fodlI1OzN5N{e3
 KB Ml[3RZBweHSxc3nzJGF{e2G7 NXW2cGhkPTEQvF2= NHLHVHIzPGh? MYHpcohq[mm2czDMbYNwNUFvaX7keYNm\CClYYPwZZNmNTNiYX7kJHBCWlBiYXP0bZZifGmxbh?= MlL2NlQ{Ozd2OUK=
 HepG2  NEHzUIFCeG:ydH;zbZMhSXO|YYm= MXexNO69VQ>? MYWyOIg> MojQdoVlfWOnczD2bY1mdnSrbjDjcIVifmGpZTDjZZV{\WRiYomgUHBU NISwdmEzPDN{NUixOi=>
fetal rat lung fibroblasts  Ml3uT4lv[XOnIFHzd4F6 MlrxPFDPxE4EoB?= M4nJV|Fp MVPpcohq[mm2czDDZZNx[XOnLUOgZYN1cX[rdIpCpC=> M1zNR|I1OzF2MUO1
PDL fibroblasts M3q2SmtqdmG|ZTDBd5NigQ>? NXLZdFdtQDEQvF5CpC=> Ml\MNYg> NF7td|lqdmirYnn0d{BE[XOyYYPlMVMh[WO2aY\peJnDqA>? MVOyOFMyPDF|NR?=
MB49 MkHVRZBweHSxc3nzJGF{e2G7 Mlm0NlDPxE1? NHXPRo8ycA>? MXPy[ZZmenOnczDDUU1qdmS3Y3XkJINmdGxiZHXheIg> MXSyOFI5OjR|Mx?=
5637 NWTpbo9NSXCxcITvd4l{KEG|c3H5 MYmyNO69VQ>? NHG2[GIycA>? NEj3SYlz\X[ncoPld{BEVS2rbnT1Z4VlKGOnbHyg[IVifGh? NHTkc3MzPDJ6MkSzNy=>
A549  M4LIdGFxd3C2b4Ppd{BCe3OjeR?= NIT1bJQyODEQvF2= MV60PIg> NInn[oV{fXCycnXzd4V{KHSqZTDhdI9xfG:|aYOgZ4F2e2WmIHL5JJBqeGW{aX7lxsA> NWC0OnV5OjR{N{KyNFE>
MCC-2 NFS0XohCeG:ydH;zbZMhSXO|YYm= NHnHc4wzOCEQvF2= NUjaeoo3Pmh? NFn4bZhFVVOR MkfaZoxw[2u|IHnu[JVk\WRiYomgd5RifXKxc4Dvdolv\SCjcH;weI9{cXNiY3XscEBl\WG2aB?= MYiyOFI3OjZ3OB?=
ADF NWfmZ4ZXSXCxcITvd4l{KEG|c3H5 MlzXOFDPxE1? M1zzXFZp NIXBTIdqdmirYnn0d{BieG:ydH;zbZMhcW6mdXPl[EBjgSClaHXtc5Rp\XKjcImgdIx2eyCcblPsNi=> NELCZWUzPDJ{OEKzNi=>
 U373  NELOWZZCeG:ydH;zbZMhSXO|YYm= M2fhc|Qx|ryP NVW3SGEyPmh? M4m5N4lvcGmkaYTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KGOqZX3veIhmemGyeTDwcJV{KFqwQ3yy NYXXco9kOjR{MkiyN|I>
RKO-HIPK2i NUm4RnRVSXCxcITvd4l{KEG|c3H5 NW\PPZpGPDEQvF2= M4mxUlZp M2HodolvcGmkaYTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KGOqZX3veIhmemGyeTDwcJV{KFqwQ3yy NGjHboQzPDJ{OEKzNi=>
HEC-1B NYW4U2RQSXCxcITvd4l{KEG|c3H5 M1;1eVIx|ryP M4rtUlFp NXXaVlI1emWmdXPld{BVWC2rbnT1Z4VlKGGyb4D0c5Nqe8LiY3HzdIF{\S1|IHHu[EBk[XOyYYPlMVk> MmDQNlQzOTN|NUi=
4T1 MVrD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M1jkOVIvPS1zMN88US=> MXq0bC=> NHv5eItFVVOR MlXEdoV{[3WnczD0bIUh[3m2b4TvfIlkcXS7IH;mJFRVOSClZXzsd{BqdmS3Y3XkJIJ6KFOSRGSgbY4h[SClb37j[Y51emG2aX;uJIRmeGWwZHXueEBu[W6wZYK= NIPiNYUzPDJyNkG2NS=>
OS  MUXBdI9xfG:|aYOgRZN{[Xl? MWGyNO69VQ>? NIrY[ZA1cA>? MXTpcohq[mm2czD0bIUh[2WubDDk[YF1cCClYYXz[YQh[nliUFTU MkK4NlQzODR7M{e=
RPE M{f1UmFxd3C2b4Ppd{BCe3OjeR?= M3j6UFExOM7:TR?= NICzXVc1QGh? MXPwZZJ1cWGubImgbY5pcWKrdIOgeIhmKGOjbIDhbY4uOSCjbnSgMVIh[WO2aY\heIlwdiCjczD3[YxtKGG|IITo[UBk[XOyYYPlJIFkfGm4YYTpc44> M1L4WFI1OjB{MEWy
UD29a MXHBdI9xfG:|aYOgRZN{[Xl? MUe1NO69VQ>? MV[yOIg> NIHwXJFqdmirYnn0d{B1cGViY3XscEBl\WG2aDDjZZV{\WRiYomgUnVVOw>? M{nLelI1OTlyNUe0
SH-SY5Y  MYjBdI9xfG:|aYOgRZN{[Xl? Mk\2NVDPxE1? M3LvOFI1cA>? MWPheJRmdnWjdHXzJINie3Cjc3WgZYN1cX[jdHnvckBidmRiY3XscEBl\WG2aDDpcoR2[2WmIHL5JGhPTS1{RFe= M33mflI1OTR3NE[z
HeLa  NGHTRWdCeG:ydH;zbZMhSXO|YYm= NUPwXGFZOTBxMkFOwG0> NUHreYppOjSq NV3kOnVIcW6qaXLpeJMhfGinIHHjeIl3cXS7IH;mJJRp\SCvYXrvdol1gSCxZjD0bIUhdWWvYnXyd{Bw\iC2aHWgZ4F{eGG|ZT3mZY1qdHl? MkPONlQyOzd{Nk[=
SCCVII  M4PW[2Fxd3C2b4Ppd{BCe3OjeR?= NEDIRWgzPc7:TR?= MWqxbC=> NVfDV2RQcW6qaXLpeJMhfGinIHPlcIwhc2mubHnu[{Bi\nSncjDkZZNifGmwaXK= M{\rbVI1OTJ4NE[0
RAW 264.7 M4PpNGFxd3C2b4Ppd{BCe3OjeR?= MV2yNO69VQ>? M2rYVVE5cA>? M2CxXYlv[3KnYYPld{BNSzNvSVmv{tIu[WO2aX6gdoF1cW9iY3;tdIFz\WRidH:gSWNVXi2PT2OgeJJm[XSvZX70JI9vdHl? MmnTNlQyOTZ5MEe=
A549  MUTBdI9xfG:|aYOgRZN{[Xl? MX[yMlXPxE1? MUWyOIg> MWrk[YNz\WG|ZYOgc5Jq\G:waX6tbY5lfWOnZDDheZRweGijZ4mgZZMhf2WubDDhcoQhVG:|czDv[kDPnM,KbTDhcJNwKG:lY4XydoVlKGS3cnnu[{BifXSxcHjh[4lkKHC{b3Pld5M> MWiyOFExOjV{Mh?=
UM-SCC-10A  MmPlRZBweHSxc3nzJGF{e2G7 M1X3e|UxyrWP MV6ybC=> MXHy[YR2[2W|IHHwc5B1d3OrczDpcoR2[2WmIHL5JIhq\2hvZH;z[UBqe2:jbHHueI9t[WO2b37l NV\Oc|VnOjRyOUi3OVM>
BGC-823 MWjBdI9xfG:|aYOgRZN{[Xl? MWqxNEDPxE1? NV7oZ3lCOjSq M3Sz[ZJm\HWlZYOgeIV1emGwZILpcoUucW6mdXPl[EBieG:ydH;zbZPDqA>? M3jBbFI1ODl6NUGx
Nalm-6  M1;yOWFxd3C2b4Ppd{BCe3OjeR?= NFvuXGYzOM7:TR?= MmK1OIg> NUXoU3R4cW6qaXLpeJMh[2G|cHHz[U05KGGwZDDjZZNx[XOnLUOgZYN1cX[jdHnvckBidmRiUFHSVE0yKGOuZXH2ZYdm M{jPTlI1ODN7OU[3
KHOS  NVTiWGh6SXCxcITvd4l{KEG|c3H5 MWS0NO69VQ>? MXKyOIg> Mn[4Zoxw[2u|IITo[UBqdmO{ZXHz[YQh[2ynYY\h[4Uhd2ZiY3HzdIF{\S1|IHHu[EBRSVKSIHnu[JVk\WRiYomgRmJOTDQEoB?= NXm3ZnBZOjRyMkWzOlE>
G292 NXTuVFhlSXCxcITvd4l{KEG|c3H5 MoPWOFDPxE1? NGezWVczPGh? MX7icI9kc3NidHjlJIlv[3KnYYPl[EBkdGWjdnHn[UBw\iClYYPwZZNmNTNiYX7kJHBCWlBiaX7keYNm\CCkeTDCRm1FO8Li Mmj1NlQxOjV|NkG=
MG-63 MkjkRZBweHSxc3nzJGF{e2G7 MXu0NO69VQ>? NWfESHpSOjSq NV6xSZQ2[myxY3vzJJRp\SCrbnPy[YF{\WRiY3zlZZZi\2Vib3[gZ4F{eGG|ZT2zJIFv\CCSQWLQJIlv\HWlZXSgZpkhSkKPRERCpC=> M2T0eVI1ODJ3M{[x
EBV-transformed B cells MXnBdI9xfG:|aYOgRZN{[Xl? NUjBRlZkOjEQvF2= MmjZNog> MkDMSG1UVw>? MXLicI9kc3NiYX70bU1ETDhyIHHu[EBidnSrLVPEPFYh[W62aXLv[JkucW6mdXPl[EBieG:ydH;zbZM> MlzCNlQxODh4Mki=
IM-9 B NX;QXoloSXCxcITvd4l{KEG|c3H5 MXyyNO69VQ>? MX2ybC=> NFz5THFFVVOR NXvmWWtb[myxY3vzJIFvfGlvQ1S4NEBidmRiYX70bU1ETDh4IHHueIljd2S7LXnu[JVk\WRiYYDvdJRwe2m| NVXGboFxOjRyMEi2Nlg>
CNE1 NFLLempCeG:ydH;zbZMhSXO|YYm= MlGyNlDPxE1? MlvIOFhp NYDjUpND[myxY3vzJGxMNUFvaX7keYNm\CCjcH;weI9{cXN? MlXINlM6QDVyMkm=
CNE2 MlLIRZBweHSxc3nzJGF{e2G7 M1njbVIx|ryP NXnlWYNpPDiq NXnxOIFu[myxY3vzJGxMNUFvaX7keYNm\CCjcH;weI9{cXN? NFjBepMzOzl6NUCyPS=>
HL-60 NX2wO|YxSXCxcITvd4l{KEG|c3H5 NUTLbY1MPTEEtV2= NEewbpMycA>? NX3zO3U4TE2VTx?= NIPJenpqdmirYnn0d{BieG:ydH;zbZMhcW6mdXPl[EBjgSCEQUG0OS=> NH7iTYUzOzl2OEe1NS=>
L929 Mm\pRZBweHSxc3nzJGF{e2G7 NXTTZ455OS5{NfMAl|XDqM7:TdMg MlXXNlRp MlSxZZVodWWwdIOgWG5H|rFvaX7keYNm\CCwZXPyc5B1d3OrczDhcoQh[XW2b4DoZYd6 MlfRNlM6PDF5Nkm=
Jurkat M4jVWGNmdGxiVnnhZoltcXS7IFHzd4F6 NWH4S|BMOs7:TR?= MYm0bC=> MV3y[ZZmenOnczDndo94fGhiaX7obYJqfGmxbjDhcoQh|rJvY3H0[Y5qdiCmZXPy[YF{\SCkeTDIV{1CW0F? M2r5Z|I{QDl4ME[x
RAW264.7  NUDJbFhUSXCxcITvd4l{KEG|c3H5 MVixNEDPxE1? MoPCNlRp NVL6U4FG\GWlcnXhd4V{KHSqZTDhdI9xfG:|aYOgbY5lfWOnZDDifUBISQ>? MmS5NlM5OjB{MEO=
A431  M{XmdGtqdmG|ZTDBd5NigQ>? NVO5WlZwPDEQvF2= MlLBNog> M1jmPIJtd2OtczDmbZNmfGmwLXnu[JVk\WRiY3zlZZZi\2Vib3[gZ4F{eGG|ZYOgZY5lKFCDUmC= NGPFOW0zOzhyMEC1PC=>
Jurkat NF\IbIdE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NV;sdoN2OjVvMUCw{txO NU[0boViPmh? MXvpcohq[mm2czD6MWZCNUOPSz3pcoR2[2WmIHPlcIwh\GWjdHi= Mn36NlM6OzN3M{K=
COS-7  NY\QRldrTnWwY4Tpc44hSXO|YYm= NEf1PWk2OML3TR?= NVHneGJtOjSq MmPNZYZn\WO2czD0bIUheHKxY3Xzd4lv\yCxZjDBWG4yeyC5aYToJJBwdHmTIITyZYN1ew>? MVyyN|k{OzJyOB?=
CAL27 MUfBdI9xfG:|aYOgRZN{[Xl? NEX5XWYyOCEQvF2= M2nlTVJp NHTkcIp{fXCycnXzd4V{KEO3cj3OVJMuemWmdXPl[EB3cWGkaXzpeJkh[nlidYCgeI8hQTBn MmjaNlM6OTd|OU[=
THP-1  NFnWVG5CeG:ydH;zbZMhSXO|YYm= NXnPbWRCOTBvNUFOwG0> MWOybC=> MljIbY5pcWKrdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkhfHKrcITvcIll\Q>? M4LzSFI{QTByMkm5
K562 NGnhNZpCeG:ydH;zbZMhSXO|YYm= Mnq0NlDPxE1? MX:0PIg> MWXpcohq[mm2czDhdI9xfG:|aYOgbY5lfWOnZDDifUA1NU2X MVeyN|g4Pjh{Nh?=
HL-60 MVjBdI9xfG:|aYOgRZN{[Xl? MkizNVAx|ryP MXiyOIg> NVfOS3I6cW6qaXLpeJMh[XCxcITvd4l{KGmwZIXj[YQh[nliYXLp[ZRidmViZHn0[ZJx\W6nc9Mg NWe4cI9{OjN6NkW3O|g>
HeLa  M1\4cWFxd3C2b4Ppd{BCe3OjeR?= MoHHNlDPxE1? MkjYNog> NV;vUJQ5cW6qaXLpeJMhTE2PUDDpcoR2[2WmIHHwc5B1d3Orcx?= M3LU[|I{QDZ|OU[2
U251 NILFboRCeG:ydH;zbZMhSXO|YYm= NEjNcYUzOM7:TR?= MV2yOIg> MmXMbY5pcWKrdIOgZ4F{fGmlaX6gbY5lfWOnZDDHNk9OKHCqYYPlJIFzemW|dDDhcoQh[XCxcITvd4l{ MUOyN|gyPjhzNh?=
HL-60 M4PzbmFxd3C2b4Ppd{BCe3OjeR?= MmL1OVDDvU1? M3HNR|Rp Mmm1Zoxw[2u|IITo[UBkdGWjdnHn[UBw\iClYYPwZZNmNTNuID25MEBidmRiUFHSVEBqdmS3Y3XkJIJ6KD[| M3nVUlI{QDB2N{C2
Ec-109 M13SXWFxd3C2b4Ppd{BCe3OjeR?= Mkn5NVAh|ryP M3Ww[lQ5cA>? NEH3dmtz\XC{ZYPz[ZMhWEVvbXXkbYF1\WRiRXOtNVA6KGOnbHygZZBweHSxc3nz MWGyN|c5OjZ2MR?=
RKO MUXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NHPsXlEyOCEQvF2= MonhNlRp MoPhbY5pcWKrdIOgeIhmKGSnY4LlZZNmKG:oIHPlcIwhfmmjYnnsbZR6KGOjdYPl[EBjgSCGQVK= M{\w[FI{PzV6ME[0
T98G MoP6R4VtdCCYaXHibYxqfHliQYPzZZk> NGfPe24yNTFyMN88US=> NUXEXWR[OjSq MnjpbY1xem:4ZYOgZ4VtdCC4aXHibYxqfHliY3;0doVifG2nboSge4l1cCCWUx?= NXPXeZh5OjN5NkmyO|U>
Jurkat NXjDZ2tIS2WubDDWbYFjcWyrdImgRZN{[Xl? NGTkcnMyODBvMkCw{txO MWCyOIg> NEPQR5BqdmirYnn0d{BJ[UF2IHnu[JVk\XNiYYDvdJRwe2m|IHTldIVv\GWwdDDv[kBkd26lZX70doF1cW:wwrC= M{fM[FI{PzN{NEix
Molt-3  MlrGRZBweHSxc3nzJGF{e2G7 MUK1NO69VQ>? NUW5NFZROmh? NHvPOVBz\WS3Y3XzJI1mdGG2b37pck1qdmS3Y3XkJIFxd3C2b4Ppdy=> NHf5OmIzOzd{NUCxNy=>
hMSC12 M1:wNmFxd3C2b4Ppd{BCe3OjeR?= Mm\LNVAx|ryP Mk\zOIQ> NYDrPY03cW6qaXLpeJMhd3O2ZX;n[Y5q[yCldXz0eZJmNWmwZIXj[YQh[2WubDDk[YF1cCCjbnSgZ4Ft[2moaXPheIlwdg>? NUf3fIpzOjN4NUe4NlI>
HM7  NWHrbYhtSXCxcITvd4l{KEG|c3H5 NFfpUHczOM7:TdMg MkPoNYg> NHjCelJjdG:la4OgZZBq[3WuYYLlckBCKGGlZYTheIUucW6mdXPl[EBk[XOyYYPlMVMh[WO2aY\heIlwdiCjbnSgVGFTWCClbHXheoFo\Q>? NV\xcI51OjN3OEO0NVI>
Hep-2  Ml;oRZBweHSxc3nzJGF{e2G7 MonHNlDPxE4EoB?= MXiyOIg> MYDEUXNQ M1XJRYFtdGW4aXH0[ZMhfGinIHTlZ5Jm[XOnIH;mJINmdGxidnnhZoltcXS7IHnu[JVk\WRiYomgd4ltcWKrbnnu M{\JVVI{PThyMEOy
HSCs M37QU2Fxd3C2b4Ppd{BCe3OjeR?= M1ruRlUx|ryP NWD5SZM{OjSq MX3EUXNQ NFvRSIVqdmirYnn0d{BvcWyxdHnubYIucW6mdXPl[EBFVkFiZHHtZYdmKGmwZHnjZZRm\CCkeTDQRXJRKGOuZXH2ZYdm M{fJU|I{PDl7OEe0
HL-60  NV7abmlIS3m2b4TvfIlkcXS7IFHzd4F6 MViyNO69VcLi MlrvNlRp M3rzOJJm\HWlZYOgeIhmKGO7dH;0c5hq[yCnZn\lZ5Qhd2ZiRYL5OS=> MkXvNlM1QTR2OEC=
HA Mkf6RZBweHSxc3nzJGF{e2G7 M4jzOlUx|ryP NXf3bXlzOjSq M{P1NJN2eHC{ZYPz[ZMhfGinIHPs[YF3[WenIH;mJHBCWlBiYX7kJINie3Cjc3WtN{whNTduIHHu[EAuQSCrbnT1Z4VlKGK7IHLvdpRmgm:vaXKvV2FJSQ>? NHrjUHYzOzR5NUm1Oi=>
C666-1 M4D0emFxd3C2b4Ppd{BCe3OjeR?= NYfMZotRPTEQvF2= MoXCNlRp NGPnUGh{fXCycnXzd4V{KHSqZTDjcIVifmGpZTDv[kBRSVKSIHHu[EBk[XOyYYPlMVMtKC15LDDhcoQhNTliaX7keYNm\CCkeTDic5J1\XqxbXniM3NCUEF? MWqyN|Q4PTl3Nh?=
Hepa1-6 MVjBdI9xfG:|aYOgRZN{[Xl? MYq1NO69VQ>? NIHTfpEzcA>? MlPWbY5pcWKrdIOgZ5Vz[3WvaX6gZY5lKHKnc4\ldoF1em:uLXnu[JVk\WRiYYDvdJRwe2m| NHrIdHkzOzR2Nke1Ny=>
PLC/PRF/5c NUjBflJUSXCxcITvd4l{KEG|c3H5 NGmwOI02OM7:TR?= NYi1U5Y3OWh? MVHwdoV3\W62czDhdI9xfG:|aYOgeJJq\2encnXkJIJ6KEOLTh?= MmjBNlM1Ozh6MkS=
HCT116 NEfwUHNCeG:ydH;zbZMhSXO|YYm= NGjX[5cyODEQvF2= MWCxMlVp M{\pO4lvcGmkaYTzJG9{NWmwZIXj[YQh[2WubDDk[YF1cA>? NFz3U|QzOzd2NEO1Ny=>
HCEC NFG3[5BHfW6ldHnvckBCe3OjeR?= NULxVXg3PTEQvF2= NXPD[JpjPzKq NHXYSZFFVVOR NXvueIl[emW|dH;y[ZMhd2ZidHjlJI5wem2jbDDIR2VEKHCqZX7veJlx\Q>? M1jOeFI{PzR{MEGx
Primary rat cerebral cortical neurons MXnBdI9xfG:|aYOgRZN{[Xl? NFTtXVYyODEQvF2= NX3jeGwyOWh? MXTwdoV3\W62czDD[E1qdmS3Y3XkJIFxd3C2b4Ppd{BidmRiY3XscEBl\WG2aB?= M3HVeFI{PzRzM{G3
MDA-MB-231  NX7KVYlUSXCxcITvd4l{KEG|c3H5 M17tTVI2|ryP M1fWNFI1cA>? M2jlVIFjem:pYYTld{BkgXSxdH;4bYNqfHliYX7kJINt\WG4YXflJI9nKGOjc4Dhd4UuOyCjbnSgVGFTWCCrbnT1Z4VlKGK7IGLnNy=> MlnJNlU{Ozd3NES=
NLRP3-Tet-on-MC/9  Ml\lRZBweHSxc3nzJGF{e2G7 M4D6blExNTRyzszN NFvWNnUyOmh? NYTMb|gy[XS2ZX71ZZRmeyC2aHWgZ4VtdCCmZXH0bEBk[XW|ZXSgZpkhS0GSUz3hd5Nw[2mjdHXkJG5NWlB|IH31eIFvfHNiaX6geIhmKFSndD3vckB{gXO2ZX2= MWeyN|cxOzN6OR?=
KNS42  MUXBdI9xfG:|aYOgRZN{[Xl? M3GxS|Ux|ryP NIPFeVIycA>? MWLy[YR2[2W|IHPlcIwh\GWjdHigZY5lKGOxbYDs[ZRmdHliYXLvcIl{cGWmIHPhd5Bie2ViMz:3JIFkfGm4aYT5JIlvKHKnc4DvcpNmKHSxIFHCWE0zPjNxMlTHM41mfG[xcn3pckBkd22kaX7heIlwdg>? MnXwNlM3QTFzNEW=
MCF-7  M2PwdGFxd3C2b4Ppd{BCe3OjeR?= MlHONlDPxE4EoB?= NULnTFRYPzKq M2HlUIlvcGmkaYTzJIVyfW:uLTDhcoQhPC2RSGStcYVlcWG2ZXSgZZBweHSxc3nz NHXzV4MzOzZ5NU[0Ny=>
hCMEC/D3  M4LjfmFxd3C2b4Ppd{BCe3OjeR?= M2mwWlI2|ryP Mn;WO|Jp MUjy[YR2[2W|IFz0fGEhcW6mdXPl[EBieG:ydH;zbZM> NITHSGEzOzZ4NUG5PC=>
Jurkat NEPRUmRCeG:ydH;zbZMhSXO|YYm= M2raWFEzNjVvNUFOwG0> M4fmUVFp MXjkc5NmKGSncHXu[IVvfGy7IIP1dJBz\XO|ZYOgV3BJNWmwZIXj[YQhWGG{LUSgZ4xm[X[jZ3WsJHBCWlBiY3zlZZZi\2VuIFTORUBnemGpbXXueIF1cW:wLDDhcoQhdG:|czDv[kB3cWGkaXzpeJk> NUf1WXFNOjN2NEK5O|Y>
CNE-1 M4DwU2Fxd3C2b4Ppd{BCe3OjeR?= NUfPfHRmOjEQvF5CpC=> NFTJW4QzPGh? NVrpPYt7cW6qaXLpeJMhWkGGMECxMYlv\HWlZXSgZ4VtdCCmZXH0bC=> NILXZpkzOzR{Nki1NC=>
HONE-1 NF3Ne49CeG:ydH;zbZMhSXO|YYm= NVjnSWh[OjEQvF5CpC=> NGL0flMzPGh? M4exR4lvcGmkaYTzJHJCTDByMT3pcoR2[2WmIHPlcIwh\GWjdHi= NGrkNlczOzR{Nki1NC=>
astrocytes cell Mkn4RZBweHSxc3nzJGF{e2G7 NWPvN3UzPDEQvF2= M1;USVZp MVTy[YR2[2W|IHXhdox6KGGyb4D0c5NqeyCrbnT1Z4VlKGK7IIP0ZZVzd3Oyb4LpcoU> MXSyN|QyOTd5OB?=
U-937 NXTYSXo1SXCxcITvd4l{KEG|c3H5 NHLXTocyOM7:TR?= MUWzNI1qdg>? MULwdoV3\W62czDUUmYucW6mdXPl[EBv\WO{b4D0c5Nqew>? NEKxOo8zOzRzMEe0PC=>
MDA-MB-231 NIfoboxCeG:ydH;zbZMhSXO|YYm= NEjDdo8yODEQvF2= Mn;UNYg> M37MR4lvcGmkaYTzJJNmdnOrdHn6ZZRqd25idH:gWHJCUUxidYDvckBOXESKIHTve44uemWpdXzheIlwdg>? MkPWNlM1ODh2Mkm=
HeLa  MlvPRZBweHSxc3nzJGF{e2G7 NIr3SpEyODEQvF2= NHTuO4ozcA>? MXHicI9kc3NiSmLTMVE2KEmwZIXj[ZMhSXCxcITveIlkKEOnbHygSIVifGh? NF7pd|czOzN2NEC0OS=>
Ec109 Ml7mRZBweHSxc3nzJGF{e2G7 NX3QRnZIOTEQvF2= MYW2bC=> M{fwe4Jtd2OtczDhdI9xfG:2aXOgZ49u[mmwYYTpc44hd2ZiVHH0MXNu[WOQNzDhcoQhemGmaXH0bY9v NWn4ZY1jOjN|M{i1Olg>
H460  MoHFRZBweHSxc3nzJGF{e2G7 NGG2VHkyOM7:TR?= MUC2bC=> NGXYXpRjdG:la4OgZZBweHSxdHnjJINwdWKrbnH0bY9vKG:oIGTheE1UdWGlTkegZY5lKHKjZHnheIlwdg>? Mme2NlM{Ozh3Nki=
HeLa  NE\iSZhCeG:ydH;zbZMhSXO|YYm= NXTP[G9OPTEQvF2= NHzHSoIyNjWq NELFeJVi[nKxZ3H0[ZPDqEOqbHHtfYRq[S2rbnT1Z4VlKGGyb4D0c5Nqew>? NVO3No9qOjN|MEO4NFQ>
SK-HEP1 MWHBdI9xfG:|aYOgRZN{[Xl? Mo\UNVAx|ryP NGnXdo0ycA>? MVrpcohq[mm2czDDdnQyKGGldHn2ZZRm\CClYYPwZZNmNTNuID23MEAuQCxiLUmsJIFv\CCyb3z5LGFFWC2{aXLvd4UqKHCxbInt[ZJie2V? M2\0bFI{OzB{NkWw
QGY7701 NHjLXWlCeG:ydH;zbZMhSXO|YYm= MXqyOe69VQ>? NHvVcHEyNjWq MWfpcohq[mm2czDhZ4N2dXWuYYTpc44hd2Zic4XiMWcyKHCqYYPlJIlv\HWlZXSgZpkhTE:[IDugdZVmemOndHnu MVeyN|I1ODB4MR?=
HepG2 NXzYcIxGSXCxcITvd4l{KEG|c3H5 NHHQXmYzOM7:TR?= Mn;3N|BucW5? MWPpcohq[mm2czD0bIUh\W6qYX7j[YQh[2WubDDk[YF1cCCkeTDjc41jcW6nZDD0doVifG2nboSgc4Yh[XCrZ3XubY4h[W6mIGTSRWlN MUOyN|IzPDJ|OR?=
U87  NWDmZ|NESXCxcITvd4l{KEG|c3H5 MWWyOe69VQ>? NY\TfldpOmh? NIPSWGZl\WO{ZXHz[ZMhcXOxbHnxeYlzcXSrZ3XubY4hMEmVTDmtbY5lfWOnZDDhdI9xfG:2aXOgZ4VtdCCmZXH0bEwh[nW2IH7veEBv\WO{b4TpZ{Bk\WyuIHTlZZRp M4XOUVI{OjJ7NkK2
HSC-2 NVW3NJJHSXCxcITvd4l{KEG|c3H5 NGnSUpozPS93MN88US=> M4jaS|Fp M1fIWolvcGmkaYTzJHNPNTN6LXnu[JVk\WRiY4n0c5RwgGmlaYT5 Mo\qNlMyPTV{NEi=
HSC-4 MmfMRZBweHSxc3nzJGF{e2G7 NW[xSphrOjVxNUFOwG0> M12zTFFp NXmzPYp[cW6qaXLpeJMhW05vM{itbY5lfWOnZDDjfZRwfG:6aXPpeJk> MXGyN|E2PTJ2OB?=
CL-1 NYj1V2VoSXCxcITvd4l{KEG|c3H5 MUGyNO69VQ>? M{DQbFFp NGjsZohjdG:la4OgU3A1PDliaX7keYNm\CClZXzsJIRm[XSq M{S5VVI{OTNzN{iy
MEL MUPBdI9xfG:|aYOgRZN{[Xl? MUSyNO69VQ>? NFrmcWMzPGh? NGrjbWRFVVOR MVjpcZBicXKnczDQNng4NWmwZIXj[YQhVUWOIHPlcIwh[XCxcITvd4l{ MU[yN|AyPDh6Nx?=
Bel-7402  MoKxR4F{eGG|ZTDBZ5RqfmG2aX;uJGF{e2G7 MV61NO69VQ>? NHT3ToozcA>? MUXpcohq[mm2czDQR2UucW6mdXPl[EBidm:ra3nz MWKyN|AxQDd2Mh?=
Eca-109 MYPBdI9xfG:|aYOgRZN{[Xl? MkLWNlXPxE1? MX[zNI1qdg>? M1rNSIlvcGmkaYTzJGJLNUJzMT3pcoR2[2WmIHPlcIwh\GWjdHi= Mm[wNlMxPzZ7Nke=
MEL MljVRZBweHSxc3nzJGF{e2G7 MUKyNO69VQ>? MV6xbC=> MlHoSG1UVw>? NIOycYZqdXCjaYLld{BROlh5LXnu[JVk\WRiTVXMJINmdGxiYYDvdJRwe2m| MYiyN|AyPDh6Nx?=
Bel-7402  NH[5PG1CeG:ydH;zbZMhSXO|YYm= MXy1NO69VQ>? NFXmSmkzcA>? MkHTbY5pcWKrdIOgVGNGNWmwZIXj[YQh[W6xaXvpdy=> M1rZZlI{ODB6N{Sy
L929 M{TvTGZ2dmO2aX;uJGF{e2G7 MnzKNk42|ryP NXHDWYRVOWh? MXXpcoNz\WG|ZYOgVmlROSCneIDy[ZN{cW:wIHHu[EBmgGGlZYLiZZRm\CCWTldOtU1qdmS3Y3XkJI1qfG:laH;u[JJq[WxiZInz[pVv[3Srb36gZY5lKFKRUzDwdo9lfWO2aX;u MViyN|AxODVzOB?=
RCC  MkTOR4VtdCCYaXHibYxqfHliQYPzZZk> M4HXVVExOM7:TR?= NXzQOosyOjSq M4n1cpJm[2:4ZYLld{B1cGVidnnhZoltcXS7IH;mJINmdGy|IHX4dI9{\WRidH:gNVVlNVCJSkK= NGHJSWozOjl7MUS5OC=>
NB2a/d1 MVvBdI9xfG:|aYOgRZN{[Xl? Mni1NVAx|ryP MkLaO|Jp NUXHUYND[XS2ZX71ZZRmeyC|dHH1do9{eG:{aX7lMYlv\HWlZXSgZ4F{eGG|ZTDhZ5Rqfmm2eTygVGFTWCxiYX7kJJRifSClbHXheoFo\Q>? NF;lXYozOjl6OEW0NS=>
T cell M1;uR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITEeHQzPS1zMEFOwG0> MVqyOIg> MV;kc5NmNWSncHXu[IVvfGy7IHnubIljcXSnZDDUJINmdGxicILvcIln\XKjdHnvckBu\WSrYYTl[EB1cHKxdXfoJJRp\SClbz3zeIlufWyjdHnvckB4cXSqIHHueIkuS0R|IHHu[EBidnSrLVPENlg> MWOyNlk5OjV|OB?=
K562 M37NbWFxd3C2b4Ppd{BCe3OjeR?= M2jtUVExOM7:TR?= NHf1S|gycA>? Mmq2Zoxw[2u|IFHico9j[X[rc3P1ceKhTi2rbnT1Z4VlKGGyb4D0c5Nqew>? MVWyNlk4OjN5Mh?=
Jurkat  MnTZRZBweHSxc3nzJGF{e2G7 NFjJXow1OM7:TR?= NH3XdWsycA>? MXLhZo9tcXOqZYOgSoF{VC2rbnT1Z4VlKGOjc4Dhd4Uh[WO2aY\heIlwdiCjbnSgZ4VtdCCmZXH0bC=> NVHrXGF2OjJ7NEK3N|g>
BGC-823 NG\VVYJCeG:ydH;zbZMhSXO|YYm= MnTYNVAx|ryP M3:3TFFp NH;zZlRx[XK2aXHscJkhemW|Y4Xld{Bk\WyuczDh[4FqdnO2IHThcYFo\SCxZjDkZYllgmWrbh?= MmnJNlI6OjZ3NEW=
Hep3B MnHZRZBweHSxc3nzJGF{e2G7 NXHpfHlSPTEQvF2= MlnxNYg> NYLiV5dw[myxY3vzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KEiHR1Pz Ml6zNlI6OjNzNUS=
LLC-PK1 NV;s[oxsSXCxcITvd4l{KEG|c3H5 MViyNO69VQ>? NF74SIUycA>? MojzdJJmfmWwdIOgZ4l{eGyjdHnuMYlv\HWlZXSg[IVoemGmYYTpc44hd2ZiQYTnOUwh[mWlbHnuMVEtKGGwZDDBeIcyOiCycn;0[Ylvew>? MkfKNlI5QTZyM{e=
A549 MX;BdI9xfG:|aYOgRZN{[Xl? NW\YO4dRPTEQvF2= NEnCVYUycA>? M4T3RYJtd2OtczD0bIUhSkGLLXnu[JVk\WRiYYDvdJRwe2m|wrC= MWKyNlg5PzJzNR?=
SGC-7901  Ml\zRZBweHSxc3nzJGF{e2G7 MYmxNO69VQ>? NWXpUWhrOjSq NYHXcVlMcW6qaXLpeJMh|rJuzsKt[Ilu\XSqeXzhZ5J6dHOqaXvvcolvNWmwZIXj[YQh[XCxcITvd4l{yqB? NFfKNXEzOjh2OEW5Oy=>
DM6 MnrkRZBweHSxc3nzJGF{e2G7 NXi0dJV3OTByzszN NGHF[XA4Omh? NILYSVFjdG:la4OgZo91cCCHMl[tNUBidmRiRULGeJIudWWmaXH0[YQh[3m2b4TvfIlkcXS7 MluyNlI5OjV|Mki=
MCF-7, MDA-MB-468, Caco-2 NE\QPY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLIUIc2OM7:TR?= MkHQOFhp NV3CSXJicW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJIlvcGmkaYTpc44hcW6mdXPl[EBjgSC|YYDvcolv NWH2R3VLOjJ6MEC5Olg>
A2750  MUTBdI9xfG:|aYOgRZN{[Xl? M4D6flIx|ryP NWTpelVIOmh? MXjEUXNQ MnXlZoxw[2u|IHPhd5Bie2ViY3zlZZZi\2ViZIXybY5oKGinbHXuZYxqdiC2cnXheI1mdnRiYX7kJJJm\HWlZYOgZZV1d3CqYXfpZ{Bk\WyuIHTlZZRp NV7ybFRSOjJ5OESzOlM>
U87  M4Lwc2Fxd3C2b4Ppd{BCe3OjeR?= MXOyNO69VQ>? MlHiNlRp M13iV5Jm\HWlZYOgeIhmKGGyb4D0c5NqeyC{YYTlJIlv\HWlZXSgZpkhWEyDQh?= M2nVT|IzPzd6N{iw
HT1080 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmP1OVDPxE1? M3rac|dl MVfpcohq[mm2czD0bIUh[2WubDDndo94fGhiaX7obYJqfGmxbjDjZZV{\WRiYomgZ49u[mmwZXSgeJJm[XSvZX70JI9nKESFQTDhcoQhV02S NFXCTpczOjd2MEm4OC=>
A549  M3fZUWFxd3C2b4Ppd{BCe3OjeR?= NXPFRYtIPTEQvF2= MYeybC=> NIKxZppx[XK2aXHscJkh\GWlcnXhd4V{KHOxZHn1cUB{\Wynbnn0[U1qdmS3Y3XkJIFxd3C2b4Ppdy=> NG\pXJAzOjd{MUiwOC=>
Primary OPC NUm4SVF5SXCxcITvd4l{KEG|c3H5 M{fScFHPxE1? NXLKPId{PmhxMkTo MUTy[YR2[2W|IITo[UBx\XKlZX70ZYdmKG:oIHPlcIx{KGmwIHXhdox6NSCjbnSgcIF1\S2jcH;weI9{cXNxbnXjdo9{cXN? M4jnSlIzPzB5M{i1
PMNs NXfCbXFPSXCxcITvd4l{KEG|c3H5 M4e2bVQx|ryP NU\RRlZsPmh? MnzUSG1UVw>? NEHmN5Fz\X[ncoPl[EB1cGViYX3veY51KG:oIHPs[YF3\WRiY3HzdIF{\S1|IITvJI5m[XJidnXobYNt\SCuZY\lcJM> NVXjNFJCOjJ4OUK1O|c>
A549  NX20b|Y3SXCxcITvd4l{KEG|c3H5 MUi1NO69VQ>? NHGzR4gycA>? NGHnOHpxemW4ZX70d{BieG:ydH;zbZMhcW6mdXPl[EBjgSCEYX;oeY9{cWSnIFm= MVGyNlY5PzZ|NR?=
AGS MkXHRZBweHSxc3nzJGF{e2G7 NVXxSmhPOjEQvF2= NIXObXUyOmh? Mn[wbY5pcWKrdIOgeIhmKGGldHn2ZZRqd25ib3[gdJJwNWOjc4Dhd4UuOyCrbjDy[ZNxd26|ZTD0c{B1cGViRYTPRYMh\nKjY4Tpc44> MV6yNlY5PzN7OB?=
shC9  M4\ENGFxd3C2b4Ppd{BCe3OjeR?= MXuxNO69VQ>? NUG1TGhZOT[q NY\EZ2Fo[my3boTzJHNJUCCneIDy[ZN{cW:wIHnuJJNpSzliY3XscJMh\Xiyb4Pl[EB1dyCnaYTo[ZIhWEFib4KgUHBE M3O5fFIzPjRzMEm0
primary MEFs NYjiZ5dxTnWwY4Tpc44hSXO|YYm= NEW4WFIyOmh? NETQUYbDqGmwY4LlZZNmeyCndH;wc5Nq\GVvaX7keYNm\CCvaYTvZ4hwdmS{aXHsJI1mdWK{YX7lJIRmeG:uYYLpfoF1cW:w NFPDPI4zOjZzM{e2Oy=>
3T9 MEFs M4XvPGZ2dmO2aX;uJGF{e2G7 M2XTR|E3cA>? MVnpcoNz\WG|ZYOgZ5l1d2Oqcn;t[UBkKHKnbHXhd4Uh[W[2ZYKg[ZRweG:|aXTlMZRz\WG2bXXueC=> M{\qU|IzPjF|N{[3
3T9 MEFs NGfkclNHfW6ldHnvckBCe3OjeR?= M3HQV|E5cA>? M1vDPZVxemWpdXzheIV{KGmwaYTpZZRweiClYYPwZZNmNTliYoX0JIRwf26{ZXf1cIF1\XNiZX\m[YN1d3JiY3HzdIF{\XNiYX\0[ZIh\XSxcH;zbYRmKHS{ZXH0cYVvfA>? NXHaN4h1OjJ4MUO3Olc>
MDA-MB-231  MorBRZBweHSxc3nzJGF{e2G7 MoXqNlDPxE1? M1;3UFRl NGnuNpNz\WS3Y3XzJJRp\SClZXzsJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KG2ndH\vdo1qdiC2cnXheI1mdnRid3HzJJNq\26rZnnjZY51dHl? NEDqWoIzOjV7M{S0NS=>
C6  M3\MSGFxd3C2b4Ppd{BCe3OjeR?= NWXEUIt1OTEQvF2= NE\ITGszPGh? NGHidXBjdG:la4OgeIhmKHO3cIDy[ZN{cX[nIHXm[oVkfCCxZjD0bIUheGWydHnk[UBwdiC4aXHibYxqfHl? NGL5eWEzOjV6OEm4NC=>
HL-60  MXXBdI9xfG:|aYOgRZN{[Xl? M{XDcFExOM7:TR?= NEjpNXczPGh? NGfhfndqdmirYnn0d{B1cGViY3XscEBieG:ydH;zbZMhe2WuZXP0[YQhMCtrLX3lcpRpgWxizsKtLFHjjpJ4KT3kbYdtfWOxcInyZY5we2mmZdMgOS=> MmjLNlI2PDZ4Nkm=
HL-60 MnLDRZBweHSxc3nzJGF{e2G7 MVexNE05OM7:TR?= NHT0dXo1cA>? MnTJbY5pcWKrdIOgWGdJWS2rbnT1Z4VlKGOnbHygZZBweHSxc3nzxsA> M1n1[VIzPTJ|MkK5
BCC NIjmVolCeG:ydH;zbZMhSXO|YYm= MlvJOVDPxE1? NHKzOlUycA>? NVnlc4xFcW6qaXLpeJMhTEGWUz3t[YRq[XSnZDDndo94fGhiaX7obYJqfGmxbh?= NGHZZY0zOjVzOUSzOi=>
RAW 264.7 Mme5RZBweHSxc3nzJGF{e2G7 MXW1NE8yODEQvF2= Mn7rNYg> MkmyZ49v[2WwdILheIlwdi2mZYDlcoRmdnRiaX7obYJqfHNiRF;OMYlv\HWlZXSgdnJPSSClbHXheoFo\Q>? NEPid5ozOjR7MUSyOi=>
K562 MVXBdI9xfG:|aYOgRZN{[Xl? M1fu[|I2|ryP MV:ybC=> M3PZc5Bz\X[nboTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KGOxLYTy[YF1dWWwdDD3bZRpKGGvdYLlcpNqdiCJIHHu[EBVWkGLTB?= MkfwNlI1QDN5N{e=
SGC-7901 MYTBdI9xfG:|aYOgRZN{[Xl? NHjWZWczOCEQvF5CpC=> MVyybC=> NFz3[I5ifHSnboXheIV{KEh{T{NCpI9zKFSQRjFOtU1qdmS3Y3XkJINmdGxiYYDvdJRwe2m|IHHzJJdmdGxiYYOgZ4F{eGG|ZT2zJIFkfGm4aYT5xsA> NHm4NFkzOjR5MUW4PS=>
PC3 NF\mPG5CeG:ydH;zbZMhSXO|YYm= NEXiTJkyOM7:TR?= NVPYNFltPGh? Mkm2Z492dnSncoOg[oxifm:lb4jp[E1qdmS3Y3XkJINie3Cjc3WtdoVt[XSnZDDhdI9xfG:|aYO= MkLjNlI1PzF7N{S=
SMMC-7721 MXHBdI9xfG:|aYOgRZN{[Xl? NILBV2I2OM7:TR?= NFy1VmE1QGh? MUXheJRmdnWjdHXzJI9VWi2rbnT1Z4VlKGGyb4D0c5Nqew>? MlH1NlI1PjV6M{O=
HeLa  MnXQRZBweHSxc3nzJGF{e2G7 M{\NSVUxyqEQvF2= NXHxeoY{PC96aB?= NHTaS45qdmirYnn0d{BUXFNvaX7keYNm\CCuYYTlMZBp[XOnIHHwc5B1d3SrYzDleoVvfHN? MUKyNlQ3ODVyNB?=
HeLa  NGrqUlZCeG:ydH;zbZMhSXO|YYm= Mo\zOVDDqM7:TR?= NYrNeHhWOWh? NIDiU3F{fXCycnXzd4V{KHSqZTDGVmFRNWmwZIXj[YQh[WOldX31cIF1cW:wIH;mJIFvdmW6aX6gWkBxd3OrdHn2[UBk\Wyucx?= M3zLWlIzPDR7NESw
T47D  Mk\2RZBweHSxc3nzJGF{e2G7 NYrhN2FvOTByzszN NF;O[FIycA>? MVPicI9kc3NidHjlJIdmdmW{YYTpc44hd2ZiRT3jZYQwS1SIMjDifUBUXFN? NWHnTGM1OjJ2MEGxOlg>
HeLa  MUPBdI9xfG:|aYOgRZN{[Xl? NVP5UG5kOzEQvF2= M{nhb|Rp M3;wPOKhcW6lcnXhd4V{KHSqZTDn[Y5memGuIHPlcIwhfmmjYnnsbZR6KDR6IHigZYZ1\XJicHjveI9lgW6jbXnjJJRz\WG2bXXueOKh MoPGNlI{QTR{NEi=
HCC NEjo[ZFCeG:ydH;zbZMhSXO|YYm= MkCxNlAh|ryPwrC= Mn:yNog> MWrheJRmdnWjdHXzJJRp\SCGSFGgbY5lfWOnZDDhZ5RqfmG2aX;uJI9nKFCDUmC= NXK2NYxKOjJ|NEK3N|I>
mESCs Mn:2RZBweHSxc3nzJGF{e2G7 MWCyMlXPxE1? NGS2eYwzcA>? M{jNUIlvcGmkaYTzJJRp\SCQYV[tcYVlcWG2ZXSgZ4F{eGG|ZTDhZ5RqfmG2aX;u MVWyNlI5PTJ5NB?=
EMT-6  NW\vOmtmS3m2b4TvfIlkcXS7IFHzd4F6 MUCxNFDPxE1? NHniXXoycA>? MVnwZZJ1cWGubImgZoxw[2unZDDj[YxtKGSnYYToJIlv\HWlZXSgZpkhe2m{YX3ld4lv\Q>? MVyyNlI2OTl{MR?=
MCF7 NIPkPGZCeG:ydH;zbZMhSXO|YYm= MV[1NOKh|ryP NFfNb4sycA>? NES0bFNqdmirYnn0d{BRSSCjY4TpeoF1\WRiY3HzdIF{\S1|LDCtPUwh[W6mIIDvcJkpSUSSLYLpZo9{\SlicH;sfY1memG|ZR?= NGf0c5MzOjJ{M{O0OS=>
K562 NF7WSJhCeG:ydH;zbZMhSXO|YYm= MoPwNlAh|ryPwrC= MXm0PIg> MlrnSG1UVw>? M{LEfoJtd2OtczDsZZBifGmwaXKtbY5lfWOnZDDpcohq[mm2aX;uJI9nKH[rYXLpcIl1gSCjbnSgZZBweHSxc3nzJIlv\HWldHnvci=> M2mxZ|IzOjF4MUW4
Molt4-hyg M4XQS2Fxd3C2b4Ppd{BCe3OjeR?= M1PYNlEx|ryP M1nSUVAvPWh? MlLGZoxw[2u|IH\hdo5me2:uLXnu[JVk\WRiY3HzdIF{\S1|LXzpb4Uh[WO2aY\peJk> NWjlZotTOjZ{N{W4NVE>
HeLa MV3BdI9xfG:|aYOgRZN{[Xl? NYHJe4w6OTEQvF2= MoPPNE42cA>? MlzxbY5pcWKrdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkhfGinIHPvcYJqdmWmIITy[YF1dWWwdDD3bZRpKGexbXnzbY4hViCjbnSgWHJCUUx? MUKyNlE4QTZ4MR?=
Jurkat T MXrBdI9xfG:|aYOgRZN{[Xl? MnfjN|DPxE1? NE[wSWExNjWq NIOwOlhFVVOR NHOyfWNjdG:la4OgeIhmKHqrcnHtMYlv\HWlZXSgZZBweHSxc3nz NF7Le2gzOjF3OUi5PC=>
Neutrophil MkHaRZBweHSxc3nzJGF{e2G7 M{j3NlIx|ryP M4XB[VAvPWh? MUfheJRmdnWjdHXzJJRp\SCycn:tZZBweHSxdHnjJIVn\mWldDDv[kBO[VJz NVHWTmg6OjZzOU[4OFQ>
HCT116 MU\BdI9xfG:|aYOgRZN{[Xl? NHHTZnk2OMLizszN M{\XZ|Jp Mn\DdoV3\XK|ZYOgd5lv\XKpaYP0bYMh[XCxcITvd4l{KGWoZnXjeJMhd2ZiY3Xs[YNwgGmkIHHu[EBPWENvMUdCpC=> MoHrNlIyPTl5NUK=
MDA-MB-231  M1v4O2Fxd3C2b4Ppd{BCe3OjeR?= NGjVbnIzNjVvNz61{txO MVKybC=> MV3pcohq[mm2czD0bIUh[2WubDDk[YF1cCCxZjDNSGEuVUJvMkOxJINmdGy|IHnu[JVk\WRiYomgV2RVKGmwIHGgZ49v[2WwdILheIlwdiCmZYDlcoRmdnRibXHucoVz NX7JZpNbOjJzMUW1NlY>
LNCaP MmDBRZBweHSxc3nzJGF{e2G7 NILTb5U1OM7:TR?= M{DUN|Jp NEHmO4RqdmirYnn0d{BjfXSnaX6gbY5lfWOnZDDj[YxtKGGyb4D0c5Nqew>? NYLDVXU{OjJzMUS3OlQ>
MB231 M{jlPWFxd3C2b4Ppd{BCe3OjeR?= NILyWJgyODEQvF2= Mk\4NYg> NH7qS5VFVVOR NGHMeI1i[nKxZ3H0[ZMhfGinIHnu[JVkfGmxbjDv[kBk\WyuIHTlZZRpKGK7IGfFSVEhcW6qaXLpeIlwdixiVGLBTWwhfHKnYYTt[Y51NCCjbnSgeIhmKGOxbXLpcoF1cW:w MXOyNlEyOjl2MB?=
HCC38  NVvXUnlxSXCxcITvd4l{KEG|c3H5 NHrlcZAyODEQvF2= NFfPcJQycA>? Mn;ySG1UVw>? NIfvUXNi[nKxZ3H0[ZMhfGinIHnu[JVkfGmxbjDv[kBk\WyuIHTlZZRpKGK7IGfFSVEhcW6qaXLpeIlwdixiVGLBTWwhfHKnYYTt[Y51NCCjbnSgeIhmKGOxbXLpcoF1cW:w M{m2WVIzOTF{OUSw
MDA-MB231 NF3tZm9CeG:ydH;zbZMhSXO|YYm= MlvrOVDDqM7:TR?= NVnrU4xlOjSq M3r1WWROW09? MlO2ZYJzd2ejdHXzJIN2emO3bXnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=> M{PKW|IzOTBzM{O1
LNCaP NYTodJdNSXCxcITvd4l{KEG|c3H5 NGnJ[Xk2OMLizszN NHjtPJAzPGh? MY\EUXNQ MlvQZYJzd2ejdHXzJIN2emO3bXnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=> M3L0UVIzOTBzM{O1
HCT116 MlzkRZBweHSxc3nzJGF{e2G7 MWG1NOKh|ryP M3;0cFI1cA>? NWj6ZZo{TE2VTx?= MoD2ZYJzd2ejdHXzJIN2emO3bXnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=> M3jtRVIzOTBzM{O1
Ishikawa  NU\1emFJSXCxcITvd4l{KEG|c3H5 M2O5WVI2|ryP Moq2NlRp MlTpdoVlfWOnczDj[YxtKGSnYYToJIFv\CCjcH;weI9{cXNiaX7keYNm\CCkeTDCZYYhSTF? MY[yNlA5QDlzOB?=
 YD-8  M1r6[mFxd3C2b4Ppd{BCe3OjeR?= NUX1N3dyOTByzszN MlrXNYg> M3TpXIlvcGmkaYTzJHBNTU9vaX7keYNm\CCjcH;weI9{cXN? NYS4W3duOjJyOE[xPFM>
eosinophil  M3jBRWFxd3C2b4Ppd{BCe3OjeR?= NYXYcYNoQTEQvF2= NWXveIVKOjSq NYnRRYdGcW6qaXLpeJMh[XCxcITvd4l{KGmwZIXj[YQh[nliRnHzJIFvfGmkb3T5xsA> NEXjNZEzOjB5OUOzOC=>
L929 MlrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXmNk42|ryP NETpenIzPGh? NV7IdGpKcW6qaXLpeJMhfGinIHX4dJJme3Orb36gc4YheC2yM{igZY5lKE6ILd86RkB1dyCjdXft[Y51KFSQRt8xMYlv\HWlZXSgcoVkem:ydH;zbZMh[W6mIHH1eI9xcGGpeR?= MWGyNlAzPzB7Nx?=
YD-8  MknYRZBweHSxc3nzJGF{e2G7 M{nlV|ExOM7:TR?= NVrMeJRbOWh? NFvkd2RjdG:la4OgeIhmKEeVLVjDcE1qdmS3Y3XkJIFxd3C2b4Ppdy=> M4DvUVIzODJyMEe4
HBx MYjBdI9xfG:|aYOgRZN{[Xl? NIn0TokzPc7:TR?= MYe0PIg> MYfEUXNQ NX;yWFR1emWmdXPl[EBk\WyuIHTlZZRpKGmwZIXj[YQh[nliMz3NRS=> MYSyNlAzODB5OB?=
U937  NYfPPWFOSXCxcITvd4l{KEG|c3H5 NYPvPHdzPTEEoN88US=> MXSxbC=> MoPGbY5pcWKrdIOgTGYucW6mdXPl[EBieG:ydH;zbZPDqA>? M1rlfFIyQTl6N{Ox
HL60 M4XhbWFxd3C2b4Ppd{BCe3OjeR?= MkfTOFDPxE1? MnnsOFBucW5? NFTaPVlFVVOR NE\EXHFjdG:la4OgRm5FSyClb33wc5Vv\HNiaX7keYNmKGW6cH;zeZJmKG:oIIDoc5NxcGG2aXT5cJNmemmwZTDhcoQhTE6DIH\yZYdu\W62YYTpc44> M4XaSVIyQTh|Mkm2
M-14 M2DofGFxd3C2b4Ppd{BCe3OjeR?= M3ziZVI2|ryP MVGwMlVp Moe0xsBqdmirYnn0d{Bjd3SqIITo[UBkenWmZTDlfJRz[WO2LTDhcoQh[2:vcH;1coQucW6mdXPl[EBieG:ydH;zbZM> MnvHNlE6PTR7NUm=
SK-BR-3 NELFN5JCeG:ydH;zbZMhSXO|YYm= MnLSOVDDqM7:TR?= M3HEW|Jp MYficI9kc3NiYYDvdJRwfGmlIFTORUBnemGpbXXueIF1cW:wIHnu[JVk\WRiYomgZ49u[mmwYYTpc44hd2ZiU12tNVY1KGGwZDDyZYRq[XSrb36= M1PCW|IyQTBzM{i2
MDA-MB-468 M3:4VmFxd3C2b4Ppd{BCe3OjeR?= M2ezNFUxyqEQvF2= M2rmZlJp MVHicI9kc3NiYYDvdJRwfGmlIFTORUBnemGpbXXueIF1cW:wIHnu[JVk\WRiYomgZ49u[mmwYYTpc44hd2ZiU12tNVY1KGGwZDDyZYRq[XSrb36= MnPONlE6ODF|OE[=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
IRF-1 / p-STAT1 / cleaved PARP1 / cleaved-caspase3; 

PubMed: 27191889     


With the addition of Z-VAD-FMK, levels of cleaved Caspase-3 and PARP1 were decreased.

Beclin1 / Atg5 / Atg7 / LC-3I / LC-3II; 

PubMed: 27191889     


Levels of Beclin1, Atg5, Atg7 and LC3-II were decreased after IFN-γ stimulation. However, when IFN-γ was combined with the caspase inhibitor, levels of Beclin1, Atg5, Atg7 and LC3-II were not decreased as determined by the Western Blot test. 

p23 / Hsp90 / hTRET / MMP2; 

PubMed: 19740745     


Expression of Hsp90 client proteins during cell death. HeLa cells were preincubated with z-VAD-fmk (100 μM) for 1 h and exposed to various concentrations of tunicamycin (Tu, in μM) for 24 h. Cell extracts were prepared and analyzed by Western blotting. β-Actin was used as the loading control.

cyto C; 

PubMed: 17301139     


z-VAD-fmk did not inhibit cytochrome c release in RRV-infected MA104 cells (RRV: rhesus rotavirus). Mock- and RRV-infected MA104 cells either were not pretreated or were pretreated with 100 μM z-VAD-fmk for 2 h before RRV infection, and treatment was continued during infection. Fourteen hours after RRV infection, the cytosolic and heavy-membrane fractions were assayed for cytochrome c by Western blotting. Mock-infected MA104 cells were used as negative controls. Cox IV and tubulin were used as protein loading controls for the heavy-membrane and cytosolic fractions, respectively. Positions of molecular weight markers are indicated on the left.

27191889 19740745 17301139
Growth inhibition assay
Cell viability; 

PubMed: 12522090     


Inhibition of magnolol-induced apoptotic cell death by z-VAD-fmk. CH27 cells were treated with cell permeable broad-spectrum caspase inhibitor (z-VAD-fmk) 2 h prior to 80 μm magnolol treatment. Cell viability was estimated. ***P<0.001, compared with the 80 μM magnolol-treated group. 

12522090
Immunofluorescence
cytochrome c ; 

PubMed: 11726499     


Immunolocalization of Smac/DIABLO and cytochrome c in HeLa cells. (A-C) Viable (non-apoptotic) HeLa cells were stained with antibodies to cytochrome c (green) and Smac/DIABLO (red) as indicated. Note that both proteins clearly co-localize within punctate, mitochondrial structures. (D–F) HeLa cells, pre-incubated with z-VAD-fmk (100 µM), were UV-irradiated followed by further incubation for 8 h. Note the cells where cytochrome c has exited mitochondria and can be seen in a diffuse pattern throughout the cell, including the nucleus (white arrows). In the latter case, note the retention of Smac/DIABLO in punctate mitochondrial structures within the cytoplasm. (G-I) HeLa cells, pre-incubated with z-VAD-fmk (100 µM), were then treated with 10 µM actinomycin D for 8 h. Once again note the retention of Smac/DIABLO in mitochondrial structures. (J-L) HeLa cells were treated as described in (G-I). A close-up of a single cell that has undergone mitochondrial cytochrome c release, but where Smac/DIABLO is retained within mitochondria, is shown.

Smac/DIABLO; 

PubMed: 11726499     


Immunolocalization of Smac/DIABLO and cytochrome c in HeLa cells. (A-C) Viable (non-apoptotic) HeLa cells were stained with antibodies to cytochrome c (green) and Smac/DIABLO (red) as indicated. Note that both proteins clearly co-localize within punctate, mitochondrial structures. (D–F) HeLa cells, pre-incubated with z-VAD-fmk (100 µM), were UV-irradiated followed by further incubation for 8 h. Note the cells where cytochrome c has exited mitochondria and can be seen in a diffuse pattern throughout the cell, including the nucleus (white arrows). In the latter case, note the retention of Smac/DIABLO in punctate mitochondrial structures within the cytoplasm. (G-I) HeLa cells, pre-incubated with z-VAD-fmk (100 µM), were then treated with 10 µM actinomycin D for 8 h. Once again note the retention of Smac/DIABLO in mitochondrial structures. (J-L) HeLa cells were treated as described in (G-I). A close-up of a single cell that has undergone mitochondrial cytochrome c release, but where Smac/DIABLO is retained within mitochondria, is shown.

Endo G; 

PubMed: 12941691     


GFP-Bax expression and immunostaining of EndoG together with nuclear Hoechst staining in HeLa cells 18 h after transient transfection with a vector encoding GFP-Bax in the absence or in the presence of the caspase inhibitor z-VAD-fmk (100 μM). 

AIF; 

PubMed: 12941691     


GFP-Bax expression and immunostaining of AIF together with nuclear Hoechst staining in HeLa cells 18 h after transient transfection with a vector encoding GFP-Bax in the absence or in the presence of the caspase inhibitor z-VAD-fmk (100 μM). 

11726499 12941691
ELISA
IL-1β; 

PubMed: 26254306     


Cell-free medium supernatants were harvested at 5 h. IL-1β levels were measured by ELISA. Z-VAD-FMK was used as a positive control. Bars represent means ± sem of pooled results from 3 experiments performed in triplicate at different times.

26254306
In vivo In vivo Z-VAD-FMK administration has been shown previously to be nontoxic and to prevent apoptosis in animal models. Intraperitoneal HK-GBS injection leads to preterm delivery, and pretreatment with Z-VAD-FMK delays preterm delivery in mice. In OVA-sensitized mice,treatment of z-VAD-fmk inhibits allergen-induced leukocyte infiltration. Systemic injection of the pan-caspase inhibitor z-VAD-fmk immediately before OVA challenge reduced inflammatory cell accumulation, mucus hypersecretion, and Th2 cytokine release in OVA-sensitized/challenged mice. Treatment with z-VAD-fmk blocked terminal differentiation of lens epithelial cells and keratinocytes, the differentiation of monocytes into macrophages, and the differentiation of erythroid progenitors. z-VAD-fmk attenuated allergen-induced airway inflammation and hyperreactivity. Treatment with z-VAD-fmk in vivo also prevented subsequent T cell activation ex vivo[7].

Protocol

Cell Research:

[6]

- Collapse
  • Cell lines: human granulosa cell lines (GC1a, HGL5, COV434)
  • Concentrations: 50 μM
  • Incubation Time: 48 h
  • Method:

    To validate the efficacy of Z-VAD-FMK, three human granulosa cell lines (GC1a, HGL5, COV434) were treated for 48 h with etoposide (50 μg/ml) and/or Z-VAD-FMK (50 μM) under normoxic conditions. To mimic the ischemic phase that occurs after ovarian fragment transplantation, cells were cultured without serum under hypoxia (1 % O2) and treated with Z-VAD-FMK. The metabolic activity of the cells was evaluated by WST-1 assay. Cell viability was determined by FACS analyses. The expression of apoptosis-related molecules was assessed by RT-qPCR and Western blot analyses.


    (Only for Reference)
Animal Research:

[7]

- Collapse
  • Animal Models: CD1 mice
  • Formulation: dissolved in DMSO, diluted in PBS (final concentration of DMSO < 1%)
  • Dosages: 10 mg/kg
  • Administration: i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 93 mg/mL (198.93 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+35 %PEG 300+2%Tween 80+ddH2O
For best results, use promptly after mixing.
6mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 467.49
Formula

C22H30FN3O7

CAS No. 187389-52-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Can you suggest an in vivo formulation of S7023 for animal studies?

  • Answer:

    For in vivo study of S7023, The IP formulation is 2% DMSO+35 % PEG 300+2% Tween 80+ddH2O up to 6 mg/ml. The gavage formula is 1%CMC-Na up to 30 mg/ml (suspensions).

  • Question 2:

    What is difference between S7023 & S8102?

  • Answer:

    Unlike S7023, S8102 does not require pretreatment with esterase for in vitro studies. This information was cited from the article: https://www.ncbi.nlm.nih.gov/pubmed/16973565.

Caspase Signaling Pathway Map

Related Caspase Products

Tags: buy Z-VAD-FMK | Z-VAD-FMK supplier | purchase Z-VAD-FMK | Z-VAD-FMK cost | Z-VAD-FMK manufacturer | order Z-VAD-FMK | Z-VAD-FMK distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID